BACKGROUND The free radical scavenger edaravone is a proven neuroprotective drug for patients with amyotrophic lateral sclerosis (ALS). Our objective was to evaluate the therapeutic effects of edaravone for oxidative stress and anti-oxidative activity in ALS patients. METHODS Twenty-two ALS patients with a disease duration of 2 years, treated by edaravone, and 25 control participants were evaluated according to their clinical scores, including ALS functional rating scale-revised (ALSFRS-R), and serum and cerebrospinal fluid (CSF) markers of oxidative stress dROM and anti-oxidative activity OXY. RESULTS Serum and CSF markers of anti-oxidative activity OXY were significantly decreased in ALS patients at pre-treatment compared with controls (##p < .01), which was improved in the course of edaravone treatment. Both serum and CSF OXY were significantly correlated with ALS clinical scores including ALSFRS-R (*p < .05, **p < .01, ***p < .001). Furthermore, serum OXY at pre-treatment was significantly correlated with a change in the ALSFRS-R score in the sixth cycle of edaravone treatment (*p < .05). CONCLUSIONS The present study suggests significant correlations between anti-oxidative activity and ALS clinical severity, and the therapeutic efficacy of edaravone for decreased anti-oxidative activity in ALS.

中文翻译：

---

依达拉奉对肌萎缩侧索硬化患者抗氧化活性降低的改善作用

背景自由基清除剂依达拉奉是一种已证实的用于肌萎缩侧索硬化（ALS）患者的神经保护药物。我们的目的是评估依达拉奉对 ALS 患者氧化应激和抗氧化活性的治疗效果。方法 采用依达拉奉治疗的 22 例病程 2 年的 ALS 患者和 25 例对照组参与者，根据其临床评分，包括 ALS 功能评定量表修订版（ALSFRS-R）、血清和脑脊液（CSF ) 氧化应激 dROM 和抗氧化活性 OXY 的标志物。结果 与对照组相比，ALS 患者在治疗前的血清和脑脊液抗氧化活性标志物 OXY 显着降低（##p < .01），在依达拉奉治疗过程中有所改善。血清和 CSF OXY 均与包括 ALSFRS-R 在内的 ALS 临床评分显着相关（* p < .05，** p < .01，*** p < .001）。此外，治疗前的血清 OXY 与依达拉奉治疗的第六个周期中 ALSFRS-R 评分的变化显着相关 (*p < .05)。结论 本研究表明，抗氧化活性与 ALS 临床严重程度之间存在显着相关性，以及依达拉奉降低 ALS 抗氧化活性的疗效。